Welcome to
RBP World!
Drugs target to STAT3
| Drug name | Drug type | Disease/phenotype | Mechanism of action(MoA) | Phase | Status | Source |
|---|---|---|---|---|---|---|
| DANVATIRSEN | Oligonucleotide | urinary bladder cancer | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | non-small cell lung carcinoma | STAT-3 mRNA 3'UTR antisense inhibitor | 2.0 | Completed | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | cancer | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Completed | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | neoplasm | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | non-small cell lung carcinoma | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | hepatocellular carcinoma | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Completed | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | diffuse large B-cell lymphoma | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Completed | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | non-small cell lung carcinoma | STAT-3 mRNA 3'UTR antisense inhibitor | 2.0 | Recruiting | ClinicalTrials |
| DANVATIRSEN | Oligonucleotide | head and neck squamous cell carcinoma | STAT-3 mRNA 3'UTR antisense inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |